Where does RGNT stock trade?

Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.

What sector and industry is RGNT in?

Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Regentis Biomaterials Ltd. go public?

Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.

What companies are similar to RGNT?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RGNT side-by-side with any of them on Quantisnow.

How can I track RGNT on Quantisnow?

Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.

RGNT

AMEX

Regentis Biomaterials Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2025

$1.51-0.11 (-6.79%)

News25/Ratings0

Price$1.51-0.04 (-2.58%)

03:30 PM07:45 PM

News · 26 weeks37-40%

2026-04-262026-10-18

Mix1290d

SEC Filings5(42%)
Market4(33%)
Other3(25%)

Latest news

25 items

4dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
5dNEWS
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technologyGelrinC is CE Mark approved in Europe, where Regentis is expanding its network of Centers of Excellence to support surgeon training and commercialization effortsEuropean clinical sites also support the Company's ongoing U.S. FDA pivotal Phase III trial HERZLIYA, ISRAEL / ACCESS Newswire / October 12, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced strong interest and engagement from orthopedic surgeons, physici
8dNEWS
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that Ehud Geller, Chief Executive Officer and Executive Chairman, will present at the 2026 ThinkEquity Conference on Thursday, October 15, 2026. Dr. Geller will be joined by Ori Gon, Chief Financial Officer, and both will be available for one-on-one meetings with investors.Dr. Geller will provide an overview of Regentis' GelrinC® technology, recent clinical developments, progress in its ongoing U.S. FDA pivotal Phase III trial, and preparations for commercialization in Europe, wh
25dSEC
SEC Form EFFECT filed by Regentis Biomaterials Ltd.
EFFECT - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
29dPR
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Ehud Geller, Executive Chairman and CEO of Regentis Biomaterials Ltd. (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solution
30dSEC
SEC Form POS AM filed by Regentis Biomaterials Ltd.
POS AM - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
36dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
36dNEWS
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026Expands European commercialization readiness, including surgeon training and regulatory approval of new manufacturing process that improves production yield 400%Strengthened balance sheet with $6.5 million private placement in June 2026 Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026Expands European commercialization readiness, including surgeon training and regulatory approval of new manufacturing process that improves production yield 400%Strengthened balance sheet with $6.5 milli
65dSEC
SEC Form SCHEDULE 13G filed by Regentis Biomaterials Ltd.
SCHEDULE 13G - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)
67dSEC
SEC Form S-8 filed by Regentis Biomaterials Ltd.
S-8 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
89dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
89dNEWS
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting, lab processing, and surgeries-potentially setting a new standard of care for knee cartilage repair HERZLIYA, IL / ACCESS Newswire / July 20, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that the Japan Patent Office has issued a Notice of Allowance for the Company's patent application titled "Organic Solvent Free Compositions Comprising Protein-Polymer
94dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
94dNEWS
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial productionGelrinC®, which is approved for sale in the European Union, is pioneering knee cartilage repair with an off-the-shelf cell-free hydrogel implant HERZLIYA, IL / ACCESS Newswire / July 15, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today it has received approval from the European Notified Body to manufacture GelrinC® using its next-generation solvent-free manufacturing process.The appro
96dSEC
SEC Form EFFECT filed by Regentis Biomaterials Ltd.
EFFECT - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
96dINSIDER
SEC Form 4 filed by Director Alpert Susan Phd Md
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
96dSEC
SEC Form 424B3 filed by Regentis Biomaterials Ltd.
424B3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
96dINSIDER
SEC Form 4 filed by Director Ben-Elazar Pini
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
96dINSIDER
SEC Form 4 filed by Director Valentine Keith
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
96dINSIDER
SEC Form 4 filed by Director Dykan Jeff
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
96dINSIDER
SEC Form 4 filed by Chief Executive Officer Geller Ehud
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
96dINSIDER
SEC Form 4 filed by Director Cohen-Arazi Efraim
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
100dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
101dSEC
SEC Form F-1 filed by Regentis Biomaterials Ltd.
F-1 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
107dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)

RGNT FAQ

5 questions

Where does RGNT stock trade?
Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.
What sector and industry is RGNT in?
Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Regentis Biomaterials Ltd. go public?
Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.
What companies are similar to RGNT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RGNT side-by-side with any of them on Quantisnow.
How can I track RGNT on Quantisnow?
Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.